Analytical Data
-
Gene name
GRA3
- Application
-
Alternative Names
P30
-
Species
Toxoplasma gondii
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
B6KEU8
-
Expression Region
43-114aa
-
Molecular Weight
10.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GRA3 is a protein associated with the intracellular parasite Toxoplasma gondii, which is notorious for its ability to manipulate host immune responses and establish chronic infections. The GRA (genetic repertoire of Toxoplasma) family of proteins, including GRA3, plays a pivotal role in the biology of T. gondii, particularly in its interaction with host cells. GRA3 is believed to contribute to the formation of the parasitophorous vacuole, where the parasite resides and proliferates, as well as modulating host cell signaling pathways to enhance the pathogen's survival. Understanding the structure and function of GRA3 is crucial for elucidating the mechanisms of pathogenesis and host-parasite interactions. Research into GRA3 may unveil potential targets for therapeutic intervention, especially given the increasing concern surrounding chronic T. gondii infections and their implications for human health, particularly in immunocompromised individuals. Furthermore, uncovering the molecular details of GRA3 can provide insights into the evolutionary adaptations of T. gondii, enhancing our understanding of its complexity as a pathogen. Given the public health impact of T. gondii and the limited treatment options available, the study of GRA3 and its potential as a vaccine candidate or therapeutic target is a significant focus within parasitology and infectious disease research.
